PHARMAESSENTIA CORPORATION Funds and ETFs PharmaEssentia Corporation
Equities
6446
TW0006446008
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 285.5 TWD | -1.04% |
|
0.00% | -17.49% |
ETFs positioned on PharmaEssentia Corporation
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.31% | 24 M€ | +6.40% | ||
| 0.12% | 0 M€ | 0.00% | - | |
| 0.04% | 2,808 M€ | +5.90% | - | |
| 0.04% | 441 M€ | +4.60% | - | |
| 0.04% | 149 M€ | +2.17% | - | |
| 0.03% | 4 M€ | -4.41% | - | |
| 0.01% | 117 M€ | +1.11% | - | |
| 0.00% | 237 M€ | +2.89% | - | |
| 0.00% | 147 M€ | +4.88% | - | |
| 0.00% | 15 M€ | +11.24% |
PharmaEssentia Corp is a Taiwan-based company mainly engaged in the research, development, production and sale of new drugs. The Company is engaged in the research and development of new drugs, which are used for treatment of hematology, such as meloproliferative neoplasms (MPN), neutropenia, anemia; infectious disease, such as hepatitis C and hepatitis B; dermatology, such as psoriasis, and neurology, such as multiple sclerosis, among others. The Companyâs products include KX01, P1101, Polycythemia Vera (PV), PEG-GCSF, PEG-EPO and others. The Company distributes its products within domestic market and to overseas markets.
Calendar
2024-05-26
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
285.5
TWD
Average target price
417.2
TWD
Spread / Average Target
+46.15%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -17.49% | 2.9B | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- 6446 Stock
- Funds and ETFs PharmaEssentia Corporation
